Gastrin-releasing peptide precursor high look needs to be combined with history, age, and clinical presentation to determine treatment options. This test is a commonly used tumor marker, most commonly seen in small cell lung cancer, often mildly elevated but with low specificity and sensitivity. The diagnosis of the disease should be based on the history, clinical manifestations and relevant auxiliary examinations such as lung CT, combined with the elevation of this test to have clinical significance, and it is recommended to follow up after one month to three months. In addition, gastrin-releasing peptide precursor is also used as a monitoring indicator for the treatment effect and prognosis of small cell lung cancer and other tumors. Patients should avoid spicy, stimulating, greasy and cold foods, quit smoking and drinking, and maintain good sleep and a stable mindset. If there is any discomfort, it is recommended that patients go to regular hospitals for consultation and treatment, and should not blindly take treatment on their own to avoid delaying the condition.